Centessa Pharmaceuticals (CNTA) Total Current Liabilities (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Total Current Liabilities data on file, last reported at $36.6 million in Q1 2026.

• Quarterly Total Current Liabilities rose 51.12% year-over-year to $36.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.6 million (up 51.12% YoY) and the FY2025 annual result came in at $42.9 million, down 25.97% from the prior year.
• Total Current Liabilities slipped to $36.6 million in Q1 2026 per CNTA's latest filing, from $42.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $58.0 million in Q4 2024 and bottomed at $24.2 million in Q1 2025.
• The 5-year median for Total Current Liabilities is $33.6 million (2022), against an average of $33.9 million.
• The widest annual swing landed in 2022, when Total Current Liabilities surged 55.61%; it then decreased 25.97% in 2025.
• Tracing CNTA's Total Current Liabilities over 5 years: stood at $38.3 million in 2022, then rose by 2.73% to $39.4 million in 2023, then surged by 47.26% to $58.0 million in 2024, then dropped by 25.97% to $42.9 million in 2025, then slipped by 14.82% to $36.6 million in 2026.
• Per Business Quant, the three latest CNTA Total Current Liabilities figures stand at $36.6 million (Q1 2026), $42.9 million (Q4 2025), and $29.1 million (Q3 2025).

Peer Comparison